Cancer Gene Therapy Market Size By Type (Ex-vivo, In-vivo) By Product (Viral Vectors {Adenoviruses, Lentiviruses, Retrovirus, Adeno Associated Virus, Herpes Simplex Virus, Vaccinia Virus}, Non-viral Vectors), By End-use (Biopharma Companies, Research Institutes), Industry Analysis Report, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2019 – 2025

Industry trends

Cancer Gene Therapy Market size surpassed $650 million in 2018 and is expected to achieve over 22.8% CAGR up to 2025.
 

Get more details on this report - Request Free Sample PDF
 

in the genes at molecular level. Gene therapy basically involves replacing abnormal or defective genes. It is a process wherein, the viruses are genetically engineered and then transferred to the host cells. Viruses are engineered to contain a specific gene that has now been widely accepted to treat cancer. The pipeline for cancer gene therapy is quite strong and recently several industry players have been focused on developing several effective cancer gene therapies and its vectors. Marketing of cancer gene therapy requires pre-marketing authorization and it is a rigorous process that is scrutinized stringently. Therefore, few cancer gene therapies are available in the market and it is still in developing phase. However, vectors, the pre-requisites of gene therapy are required for gene transfer are increasingly being adopted for research and treatment purposes.
 

Cancer gene therapy industry can be traced back to 1960’s that marks the development of viral vectors. After several years, in 1983, scientists from Texas proposed a gene therapy. Later, as the technology advanced, cancer gene therapy started gaining momentum. In 1990, scientists started working on melanoma by modifying the genes in white blood cells. French Anderson carried out long term clinical trials to study the efficacy of cancer gene therapy. Currently, industry players have developed cancer gene therapies such as Kymriah that have been approved in the U.S. However, few cancer gene therapies are still in the clinical trials phase and have the potential to receive marketing approval.
 

Improving regulatory scenario has surged the cancer gene therapy market growth

Improving regulatory scenario will boost the cancer gene therapy industry growth during analysis timeframe. Regulations are imposed on the manufacturers to ensure entry of defect free products (vectors) to the market since, they are directly associated with the health of individuals. Any defects in the gene therapy products could prove fatal for the patients hence, laws are amended such that no products are recalled during post-marketing surveillance. Therefore, increasing availability of superior quality cancer gene therapy will augment the cancer regenerative medicine market growth in the forthcoming years.
 

High cost of cancer gene therapy may create affordability issues thereby, restraining the cancer gene therapy market growth. People in emerging economies having low purchasing power would refrain themselves from purchasing expensive cancer gene therapy products. However, this factor would have mid-term impact on the cancer gene therapy industry growth and will vanish with an increase in the income level.
 

Ex-vivo cancer gene therapy with commendable efficiency captured significant market share

Based on the type, cancer gene therapy market share can be bifurcated into ex-vivo and in-vivo therapy. Ex-vivo cancer gene therapy segment held around 45% revenue share owing to its rising adoption in treatment of blood cancer. It involves genetic modification of cells outside the body that increases the stability of treatment. In contrast, in-vivo gene therapy involves gene transfer in the individual’s body that may directly interfere with normal protein transcription as well as translational process. Therefore, due to the benefits offered by ex-vivo cancer gene therapy, it is preferred by the healthcare professionals thereby, stimulating the segmental growth.
 

Non-viral vectors have geared up the efficiency of cancer gene therapy

Products required for cancer gene therapy include viral and non-viral vectors. Non-viral vectors segment is expected to foresee over 23% growth throughout the analysis timeframe. Considerable segment growth can be attributed to the advantages possessed by viral vectors. Non-viral vectors are highly efficient as compared to the viral vectors. Moreover, these vectors have low toxicity and immunogenicity that reduces the risks of infections and allergies in patients suffering from cancer. Above mentioned factors should escalate the business growth in coming years.
 

Biopharmaceutical companies have significant inclination towards viral vectors for developing novel therapies

Get more details on this report - Request Free Sample PDF
 

By end-use, the cancer gene therapy market share is segmented into biopharmaceutical companies, research institutes and others. Biopharmaceutical segment of the market was valued around USD 330 million in 2018 and will experience significant growth in the coming years. Biopharmaceutical companies require viral as well as non-viral vectors utilized in developing drugs and therapies for treating cancer. Moreover, companies such as Novartis rely on vectors for conducting clinical trials to check the efficiency of therapies that are developed. Therefore, growing adoption of vectors by biopharmaceutical companies will spur the business growth.
 

Increasing prevalence of cancer in developed economies such as Germany and U.S. will prove beneficial for the cancer gene therapy industry growth.

Get more details on this report - Request Free Sample PDF
 

Germany cancer gene therapy market was valued around USD 30 million in 2018 and is yet to witness numerous growth opportunities in the forthcoming years. Improving regulatory scenario is one of the major factors driving country growth. Regulatory authorities in Germany have simplified the regulatory process since past few years that has helped the industry players to promote their therapies in Germany easily. Moreover, rising inclination towards the availability of advanced cancer gene therapy amongst healthcare professionals will foster the country growth.
 

The U.S. market will experience around 22% growth during the forecast period. Increasing prevalence of cancer will stimulate the demand for cancer gene therapies. According to American Cancer Society, in 2016, around 15 million cancer cases were diagnosed and the number of people suffering from cancer is still growing. This scenario proves beneficial for the country growth as it raises the demand for effective cancer gene therapies. Furthermore, researchers also actively focus on developing gene therapies. Government also motivate the researchers by providing funds  to introduce innovation in the cancer gene therapy. Above mentioned factors will spur the country growth.
 

bluebird bio is one of the leading companies in cancer gene therapy market owing to continuous innovations

Few of the notable players operating in the industry are Sirion Biotech, Vigene Biosciences, bluebird bio, Ziopharm, Cellectis, Cobra, Finvector, Uniqure, Sarepta Therapeutics, Caribou among others. These players are implementing various strategies such as product launches, acquisitions and collaborations, in order to capture high revenue share in cancer gene therapy business.
 

Some of the recent industry developments:

• In January 2015, Novartis in collaboration with Caribou developed platforms for gene therapies. Such collaborations will enhance Novartis’s portfolio and will foster its growth in near future.
   
• In June 2014, Pfizer entered into strategic collaboration with Cellectis to develop cancer therapies. This strategic initiative will not only provide competitive advantage to both the companies but also boost their profits.
   

Cancer gene therapy market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2014 to 2025, for the following segments:

By Type

• Ex-vivo
• In-vivo

By Product

• Viral Vectors
  • Adenoviruses
  • Lentiviruses
  • Retrovirus
  • Adeno Associated Virus
  • Herpes Simplex Virus
  • Vaccinia Virus
  • Others
• Non-viral Vectors
• Others

By End-use

• Biopharma companies
• Research institutes
• Others

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
• Asia Pacific
  • China
  • Japan

• Rest of the World